

# Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

---

**(GLORIA-AF) Romiti, Giulio Francesco; ...; Kes, Vanja Basic; Kalan, Marica Bracic; Brkljacic, Diana Delic; Knezevic, Aleksandar; Kovacic, Dragan; Nazlić, Jurica; Persic, Viktor; Pivac, Nediljko; ...**

*Source / Izvornik:* **eClinicalMedicine, 2023, 63**

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.1016/j.eclinm.2023.102039>

*Permanent link / Trajna poveznica:* <https://um.nsk.hr/um:nbn:hr:220:708360>

*Rights / Prava:* [In copyright](#)/[Zaštićeno autorskim pravom.](#)

*Download date / Datum preuzimanja:* **2025-02-23**



*Repository / Repozitorij:*

[Repository of the Sestre milosrdnice University Hospital Center - KBCSM Repository](#)

# Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry



Giulio Francesco Romiti,<sup>a,b,o</sup> Bernadette Corica,<sup>a,b,o</sup> Marco Proietti,<sup>a,c,d</sup> Davide Antonio Mei,<sup>a,e</sup> Juliane Frydenlund,<sup>f</sup> Arnaud Bisson,<sup>a,g</sup> Giuseppe Boriani,<sup>e</sup> Brian Olshansky,<sup>h</sup> Yi-Hsin Chan,<sup>ij,k</sup> Menno V. Huisman,<sup>l</sup> Tze-Fan Chao,<sup>m,n,\*</sup> and Gregory Y. H. Lip,<sup>a,f,n,\*\*</sup> on behalf of the GLORIA-AF Investigators<sup>p</sup>



<sup>a</sup>Liverpool Centre for Cardiovascular Sciences at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

<sup>b</sup>Department of Translational and Precision Medicine, Sapienza – University of Rome, Rome, Italy

<sup>c</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

<sup>d</sup>Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy

<sup>e</sup>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy

<sup>f</sup>Danish Center for Clinical Health Services Research, Aalborg University, Aalborg, Denmark

<sup>g</sup>Service de Cardiologie, CHU Trousseau et Université François Rabelais, Tours, France

<sup>h</sup>Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, USA

<sup>i</sup>Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan

<sup>j</sup>College of Medicine, Chang Gung University, Taoyuan City, Taiwan

<sup>k</sup>Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan

<sup>l</sup>Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands

<sup>m</sup>Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

<sup>n</sup>Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

## Summary

**Background** Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study.

**Methods** From the GLORIA-AF Registry Phase II–III (November 2011–December 2014 for Phase II, and January 2014–December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with [ClinicalTrials.gov](https://clinicaltrials.gov), NCT01468701, NCT01671007, and NCT01937377.

**Findings** 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals [CI]: 0.23 [0.22–0.25] and 0.66 [0.61–0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67–1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76–0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding.

eClinicalMedicine

2023;63: 102039

Published Online 25

August 2023

<https://doi.org/10.1016/j.eclinm.2023.102039>

1016/j.eclinm.2023.

102039

\*Corresponding author. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

\*\*Corresponding author. Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom.

E-mail addresses: [tfchao@vghtpe.gov.tw](mailto:tfchao@vghtpe.gov.tw) (T.-F. Chao), [gregory.lip@liverpool.ac.uk](mailto:gregory.lip@liverpool.ac.uk) (G.Y.H. Lip).

<sup>o</sup>Joint first authors.

<sup>p</sup>Study group are listed in the [appendix](#).

**Interpretation** Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis.

**Funding** The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH.

**Copyright** © 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

**Keywords:** Atrial fibrillation; Ethnic differences; Asia; Oral anticoagulant; Outcomes

### Research in context

#### Evidence before this study

We searched PubMed from inception to April 30, 2023, without language restrictions, for randomised trials, systematic reviews, meta-analyses, and observational studies, using the terms “Atrial Fibrillation” and “Asian”. Ethnic differences have been described in patients with Atrial Fibrillation, with Asian individuals found more frequently undertreated with oral anticoagulant, and with different risk of long-term outcomes. Epidemiological data, and our understanding of the differences between Asian and non-Asian patients with AF, are still limited.

#### Added value of this study

In this large analysis including more than 34,000 patients with AF, we found that Asian ethnicity was associated with

lower odds of oral anticoagulant prescription, higher risk of treatment discontinuation, and an overall different prognosis (with lower risk of the primary composite outcome of all-cause death and major adverse cardiovascular events, but higher risk of thromboembolism and intracerebral haemorrhage).

#### Implications of all the available evidence

Asian patients with AF are often suboptimally managed for thromboembolic risk prevention, and show a specific prognostic risk profile. Acknowledging ethnic differences in the natural history of AF is pivotal to ensure equal and optimal care and to improve outcomes of AF patients.

## Introduction

With progressive ageing of the population, the incidence of AF is increasing, with prevalence projected to reach over 17 million individuals in Europe and 72 million in Asia by 2050.<sup>1,2</sup> Despite improvements in the treatment of AF, the risks of adverse outcomes and healthcare costs are still high.<sup>3–5</sup>

Importantly, regional differences in the epidemiology and natural history of AF are increasingly reported, including different age at onset, and predisposition to AF-related adverse events.<sup>6</sup> Asian countries report a lower prevalence of AF compared to Western ones, although the risk of thromboembolic events and intracranial bleeding seems higher in Asian patients.<sup>6–9</sup>

The large-scale uptake of non-vitamin K antagonist oral anticoagulants (NOACs) in clinical practice have progressively led to a paradigm shift for stroke prevention of patients with AF, and data from post-hoc analysis of randomised controlled trials have shown that NOACs may provide significant benefit (both in terms of efficacy and safety) in Asian patients, compared to vitamin K antagonist (VKA).<sup>7,10–12</sup>

However, there are still relatively limited epidemiological data on Asian patients,<sup>8</sup> and previous reports have identified potential ethnic differences in the uptake of oral anticoagulant (OAC), with potential undertreatment

of Asian patients.<sup>13</sup> Indeed, one previous analysis from the Phase III of the prospective Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) showed regional-based differences in OAC use among patients with AF.<sup>14</sup>

In this analysis, using data from both Phase II and Phase III of the GLORIA-AF Registry, we compared Asian vs. non-Asian patients with AF, in terms of OAC prescription, risk of OAC discontinuation, and incidence of major adverse events.

## Methods

### Study design

The design of GLORIA-AF Phase II and III registry have been previously reported.<sup>15</sup> In short, GLORIA-AF is an international, multicentre prospective registry program structured in 3 phases, aiming at assessing the long-term effectiveness and safety of dabigatran etexilate in real-world patients with AF. During the study period (November 2011–December 2014 for Phase II, and January 2014–December 2016 for Phase III), patients with newly-diagnosed non-valvular AF and CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1 were consecutively enrolled in the study. The primary results of the GLORIA-AF Phase III registry have already been published.<sup>16,17</sup> The original

studies were registered with [ClinicalTrials.gov](https://clinicaltrials.gov), NCT01468701, NCT01671007, and NCT01937377.

### Inclusion/exclusion criteria and procedures

Full details on inclusion and exclusion criteria are reported elsewhere.<sup>17</sup> Briefly, eligible patients for the inclusion in both Phase II and Phase III of the GLORIA-AF registry were adult patients ( $\geq 18$  years), with a recent diagnosis of AF ( $< 3$  months, or  $< 4.5$  months only in Latin America), and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 1$ , who provided written informed consent. Main exclusion criteria were: mechanical heart valve (or expected to undergo valve replacement); having received VKA for  $> 60$  days in the lifetime; having other clinical indication for OAC; short life expectancy ( $< 1$  year); or AF due to a reversible cause.

The study was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki, and approved by local institutional review board at participating sites. At baseline, data regarding demographics (including self-reported ethnicity), comorbidities, and treatment prescribed were recorded by investigators, for each patient, in standardised electronic case report forms.

### Definition of Asian ethnicity

For this analysis, we included only those patients with available data regarding ethnicity (i.e., being Asian or not). Ethnicity was self-reported by patients and collected in the electronic case report form. Specifically, patients were able to select “Asian” among the ethnicities proposed (which included also American Indian/American Native/Alaska Native, Black/African American, White, Native Hawaiian/Other Pacific Islander, Arab/Middle East, African and Other), and if so, they were also able to sub-specify whether they were Chinese, Japanese, Korean, other Asian or South Asian. As these two last categories accounted for  $< 1\%$  of total patients, for purposes of this analysis, we grouped them together among “other Asian”.

For all the comparisons, the reference group was the one composed of non-Asians patients, which encompassed all other ethnicities (i.e., White, Black/African American, and others).

### Treatment, follow-up and major adverse outcomes

At the baseline, data on antithrombotic prescription was collected by investigators. Details on follow-up and outcomes for GLORIA-AF Phase II and Phase III were reported elsewhere.<sup>17,18</sup> Briefly, patients who received dabigatran during Phase II were followed-up for 2 years, while all patients enrolled during the Phase III of the program were followed-up, irrespective of the antithrombotic treatment received at baseline, for 3 years. During follow-up, data regarding OAC discontinuation and major outcomes were recorded, until study withdrawal, death or end of the study. In this analysis, we

evaluated non-persistence and discontinuation only for patients who received OAC at baseline. We defined OAC discontinuation as either switching to another antithrombotic regimen (including switching to a different OAC), or interruption  $\geq 30$ -days of the treatment received at baseline. Dose changes were not considered discontinuation. We defined non-persistence as either discontinuation or study termination.

We also evaluated the associations between ethnicity and the risk of major outcomes occurred during follow-up. For this analysis, we defined our primary outcome as the composite of all-cause death and MACEs (defined as the occurrence of cardiovascular death, stroke, and myocardial infarction). We also investigated the following exploratory secondary outcomes:

- All-cause death;
- Cardiovascular death;
- Stroke (haemorrhagic, ischemic, and uncertain classification strokes);
- Thromboembolism (composite of stroke, transient ischemic attack (TIA), and other non-central nervous system thromboembolism),
- Major Adverse Cardiovascular Events (MACEs)
- Major bleeding (defined according to the International Society of Thrombosis and Haemostasis classification, i.e., overt bleeding associated with a haemoglobin reduction of  $\geq 20$  g/L or leading to  $\geq 2$ -unit of blood transfusion, symptomatic bleeding in a critical organ, life-threatening or fatal bleeding).
- Among major bleeding events, we evaluated the subgroup of intracranial haemorrhages (ICH), defined as intracranial subdural, epidural, subarachnoid, intraventricular, intracerebral and non-specified bleeding), and non-ICH major bleedings.

### Statistical analysis

Continuous variables were reported as mean and standard deviation (SD) or median and interquartile range [IQR] and compared with appropriate parametric and non-parametric tests according to whether they were normally distributed or not, respectively. Categorical variables, reported as frequencies and percentages, were compared using chi-square test.

The associations between Asian ethnicity and prescription of OAC at baseline were analysed through multivariable logistic regression; results were reported as Odds Ratio (OR) and 95% Confidence Intervals (CI). Cox-regression models were used to evaluate the association between Asian ethnicity and both OAC discontinuation and risk of outcomes, and results were presented as Hazard Ratio (HR) and 95% CI. For both logistic and Cox regression models, we analysed two set of multivariable models: in the first (main model) we included the following covariates: age, sex, type of AF (paroxysmal, persistent or permanent), history of previous bleeding, body mass index (BMI) and CHA<sub>2</sub>DS<sub>2</sub>-

VASc score; in the second (model 2), we included the same covariates of model 1, replacing CHA<sub>2</sub>DS<sub>2</sub>-VASc with the individual comorbidities which compose the score (history of stroke/TIA, heart failure, arterial hypertension, diabetes, peripheral vascular disease, and coronary artery disease). Additionally, for the analysis on major outcomes, we also adjusted models for the use of OAC. Finally, we calculated incidence rates (IR) and 95% CI according to the number of events and person-years.<sup>19</sup> For the primary outcome, we reported Kaplan-Meier curves. Survival distributions were compared using Log-Rank test.

We performed additional analyses. For all outcomes investigated (OAC prescription and discontinuation, risk of major outcomes), we analysed the Asian ethnicity subgroups, as previously defined, and we also evaluated the interaction between Asian ethnicity and the phase of enrolment (Phase II vs. Phase III).

A two-sided  $p < 0.05$  was considered statistically significant. All the analyses were performed using R 4.0.3 (R Core Team 2020, Vienna, Austria).

#### Role of the funding source

The GLORIA-AF Registry was funded by Boehringer Ingelheim. The authors are solely responsible for the design and conduct of this study, all study analyses, drafting and editing of the manuscript, and its final content. GFR, BC and GYHL had access to dataset and decided to submit the manuscript. All authors supported the decision to submit the manuscript for publication.

#### Results

From the 36,617 patients originally enrolled in the GLORIA-AF Phase II and III Registry, 34,421 (94.0%; mean age 70.0 (10.5) years, 15,518 (45.1%) females) with available data on self-reported ethnicity were included in this analysis. Of these, 6900 (20%) were Asian: 3829 were Chinese (55.5% of the total Asian group), 1964 Korean (28.5%), 814 Japanese (11.8%) and 293 other Asians (4.2%). Among non-Asian patients, the vast majority (91.3%) were White.

Baseline characteristics according to ethnicity (Asian vs. non-Asian) and subgroups are reported in [Supplementary Table S1 and S2](#) in Supplementary Materials. Asian patients were younger, less likely female, showed lower BMI values, and had an overall lower burden of most comorbidities. Accordingly, baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores were significantly lower among Asian patients.

Several differences were also observed among subgroups of Asian patients, with Japanese patients being older, and Korean patients having a lower prevalence of most comorbidities. Overall, most Asian patients were recruited in Asia (97.1%). Among the ethnic subgroups, those who were included in the “other Asian” subgroup were mostly recruited outside Asia (45.7%).

#### Patterns of OAC prescription

Rates of antithrombotic prescription by ethnicity groups are reported in [Fig. 1](#). Asian patients were less likely prescribed an OAC (57.3% vs. 86.7% in non-Asian), including NOACs (34.7% vs. 58.2%). Consistently, they were more likely not treated with antithrombotic therapy, or treated with antiplatelet drugs. A significant heterogeneity in the pattern of OAC use was observed among Asian ethnicity subgroups, with Japanese patients more frequently treated with OACs (90.3%), specifically NOACs (85.7%), and less likely to receive VKAs, antiplatelet drugs or no antithrombotic treatment; Overall OAC prescription rate was lower in the other ethnic subgroups (74.1% in other Asians, 66.8% in Korean, and 44.0% in Chinese patients). Similar findings were observed for NOAC prescription.

Results of multivariable logistic regression regarding OAC prescription are reported in [Table 1](#). Compared to non-Asian patients, Asian individuals were less likely treated with OAC (OR: 0.23, 95% CI: 0.22–0.25). Similar results were observed (although with different magnitude) for Chinese, Korean, and other Asian patients. Conversely, Japanese patients had higher odds of receiving an OAC (OR: 1.83, 95% CI: 1.41–2.42). Model 2 gave broadly consistent results.


Among those prescribed an OAC, Asian patients were less likely treated with NOAC (OR: 0.66, 95% CI: 0.61–0.71) compared to non-Asians; similar results were observed for Chinese (OR: 0.55, 95% CI: 0.49–0.61), Korean (OR: 0.39, 95% CI: 0.34–0.44) and other Asian (OR: 0.58, 95% CI: 0.44–0.77) subgroups, while Japanese patients showed a higher likelihood of receiving NOAC compared to VKA (OR: 10.01, 95% CI: 7.04–14.81). Model 2 gave similar estimates ([Table 1](#)).

Analysing the results according to the enrolment phase (Phase II vs. Phase III), we found lower odds of receiving OAC and NOAC in Asian patients enrolled in Phase II ( $p$  for interaction  $< 0.001$  for both). Similar results were observed for OAC prescription in Chinese and Korean patients, with Chinese patients recruited in Phase III, and Korean patients recruited in Phase II less likely to receive NOAC ( $p < 0.001$  for both, [Supplementary Fig. S2](#)).

#### OAC persistence and discontinuation

Among 27,793 patients who received OAC at baseline, 20,768 (74.7%) had complete follow-up data on OAC discontinuation. Rates of OAC persistence and discontinuation at 6, 12 and 24 months are reported in [Supplementary Fig. S3](#) for Asians vs. non-Asians and [Supplementary Fig. S4](#) for Asian subgroups, respectively.

Cox-regression models showed a higher risk of OAC discontinuation in Asian patients (HR: 1.79, 95% CI: 1.67–1.92), specifically in Chinese (HR: 2.18, 95% CI: 2.00–2.37), Japanese (HR: 1.30, 95% CI: 1.10–1.53) and



**Fig. 1: Rates of antithrombotics prescribed according to Asian ethnicity.** Legend: NOAC = Non vitamin-K antagonist oral anticoagulant; VKA = vitamin K antagonist.

Korean (HR: 1.58, 95% CI: 1.39–1.80) patients (Table 2). Regression model 2 provided similar estimates. No statistically significant interaction was observed between phase of recruitment and risk of OAC discontinuation in Asian patients (Supplementary Fig. S5). Among Asian ethnicity subgroups, Chinese patients recruited during Phase III, and Korean patients recruited during Phase II were more likely to discontinue OAC (p for interaction = 0.026 and 0.002, respectively) (Supplementary Fig. S6).

The analysis on the risk of OAC discontinuation according to OAC type received at baseline provided broadly similar results (Table 2), although with differences in magnitude of association; no statistically significant differences were observed for Japanese and other Asians patients prescribed with VKA.

**Risk of adverse outcomes**

Overall, 24,383 patients (70.8%) had complete follow-up data on the primary outcome and were included in the survival analysis; 4526 (18.6%) were Asian. Compared to patients included, those excluded from this analysis were more likely Asian (p < 0.001) and of female sex (p = 0.017). There were no statistically significant differences in terms of age and proportion of those with high thromboembolic risk (i.e., CHA<sub>2</sub>DS<sub>2</sub>-VASc Score ≥ 2).

During a median follow-up of 36.2 [IQR: 26.3–37.5] months, a total of 2733 (11.2%) primary composite outcome events were observed. Kaplan–Meier curves for the primary composite outcome according to Asian ethnicity and subgroups are reported in Fig. 2, panels A and B, respectively. Non-Asian patients had a higher incidence of the primary composite outcome compared

	Asian ethnicity				
	Asian (vs. non-Asian) OR [95% CI]	Chinese (vs. non-Asian) OR [95% CI]	Japanese (vs. non-Asian) OR [95% CI]	Korean (vs. non-Asian) OR [95% CI]	Other Asian (vs. non-Asian) OR [95% CI]
<b>OAC prescription</b>					
Model 1	0.23 [0.22–0.25]	0.14 [0.12–0.15]	1.83 [1.41–2.42]	0.37 [0.33–0.42]	0.49 [0.37–0.65]
Model 2	0.22 [0.21–0.24]	0.14 [0.13–0.15]	1.66 [1.27–2.20]	0.35 [0.31–0.39]	0.48 [0.36–0.64]
<b>NOAC vs. VKA prescription</b>					
Model 1	0.66 [0.61–0.71]	0.55 [0.49–0.61]	10.01 [7.04–14.81]	0.39 [0.34–0.44]	0.58 [0.44–0.77]
Model 2	0.64 [0.59–0.69]	0.53 [0.48–0.59]	9.51 [6.68–14.08]	0.38 [0.34–0.43]	0.55 [0.41–0.73]

Bold text depicts statistically significant results at p < 0.05 level. Model 1 adjusted for age, sex, type of AF, history of bleeding, BMI, CHA<sub>2</sub>DS<sub>2</sub>-VASc score and Phase of Recruitment (Phase III vs. Phase II). Model 2 adjusted for age, sex, type of AF, history of bleeding, BMI, arterial hypertension, diabetes, history of stroke/TIA, heart failure, PAD, CAD and Phase of Recruitment (Phase III vs. Phase II). CI = confidence intervals; OAC = oral anticoagulant; OR = odds ratio; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.

**Table 1: Multivariable logistic regression on OAC prescription according to Asian ethnicity group and subgroups.**

	Asian ethnicity				
	Asian (vs. Non-Asian) HR [95% CI]	Chinese (vs. non-Asian) HR [95% CI]	Japanese (vs. non-Asian) HR [95% CI]	Korean (vs. non-Asian) HR [95% CI]	Other Asian (vs. non-Asian) HR [95% CI]
<b>OAC discontinuation</b>					
Model 1	<b>1.79 [1.67-1.92]</b>	<b>2.18 [2.00-2.37]</b>	<b>1.30 [1.10-1.53]</b>	<b>1.58 [1.39-1.80]</b>	1.04 [0.75-1.44]
Model 2	<b>1.81 [1.68-1.94]</b>	<b>2.17 [1.99-2.37]</b>	<b>1.23 [1.12-1.57]</b>	<b>1.62 [1.42-1.84]</b>	1.04 [0.74-1.45]
<b>NOAC discontinuation</b>					
Model 1	<b>1.89 [1.73-2.05]</b>	<b>2.61 [2.36-2.90]</b>	<b>1.39 [1.17-1.65]</b>	<b>1.48 [1.27-1.73]</b>	0.84 [0.53-1.33]
Model 2	<b>1.93 [1.77-2.10]</b>	<b>2.63 [2.37-2.92]</b>	<b>1.42 [1.19-1.69]</b>	<b>1.53 [1.31-1.79]</b>	0.83 [0.51-1.34]
<b>VKA discontinuation</b>					
Model 1	<b>1.47 [1.28-1.69]</b>	<b>1.41 [1.21-1.65]</b>	1.27 [0.48-3.40]	<b>1.79 [1.42-2.27]</b>	1.22 [0.76-1.94]
Model 2	<b>1.44 [1.25-1.66]</b>	<b>1.37 [1.17-1.60]</b>	1.22 [0.45-3.26]	<b>1.79 [1.42-2.27]</b>	1.21 [0.76-1.94]

Bold text depicts statistically significant results at  $p < 0.05$  level. Model 1 adjusted for age, sex, type of AF, history of bleeding, BMI, CHA2DS2-VASc score and Phase of Recruitment (Phase III vs. Phase II). Model 2 adjusted for age, sex, type of AF, history of bleeding, BMI, arterial hypertension, diabetes, history of stroke/TIA, heart failure, PAD, CAD and Phase of Recruitment (Phase III vs. Phase II). CI = confidence intervals; HR = hazard ratio; OAC = oral anticoagulant; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.

**Table 2: Multivariable Cox regression on OAC discontinuation according to Asian ethnicity.**


to Asian individuals ( $p < 0.001$ ); among the ethnicity subgroups, Japanese and Korean patients showed lower incidence of the primary outcome, while patients in the other Asian subgroups had the highest incidence ( $p < 0.001$ ).

Multivariable Cox regression analysis showed that Asian ethnicity was associated with a lower risk of the primary composite outcome (HR: 0.86, 95% CI: 0.76–0.96; Table 3). Similar results were observed when comparing Japanese and Korean subgroups with non-Asian patients (HR: 0.53, 95% CI: 0.36–0.78 and HR: 0.42, 95% CI: 0.30–0.59), while no statistically significant differences were observed between Chinese and

non-Asian patients (Table 3). Finally, patients in the other Asian subgroup showed a higher hazard of the primary composite outcome (HR: 1.47, 95% CI: 1.06–2.06). Model 2 provided similar estimates.

**Exploratory secondary outcomes**

Asian ethnicity group was associated with lower risk of all-cause death (HR: 0.67, 95% CI: 0.58–0.78), major bleeding (HR: 0.77, 95% CI: 0.61–0.98) and non-ICH major bleeding (HR: 0.51, 95% CI: 0.37–0.71), and with higher risk of thromboembolism (HR: 1.33, 95% CI: 1.10–1.61), and ICH (HR: 1.54, 95% CI: 1.04–2.26) (Table 3). Among the Asian ethnicity subgroup, Korean



**Fig. 2: Survival curves for the primary composite outcome of all-cause death and MACE according to Asian ethnicity.** Legend: Panel A: Asian vs. non-Asian; Panel B: Asian Ethnicity subgroups vs. non-Asian. Log-Rank  $p < 0.001$  for both.

	Asian ethnicity					
	non-Asian (n = 19,857)	Asian (n = 4526)	Chinese (n = 2712)	Japanese (n = 610)	Korean (n = 1014)	Other Asian (n = 190)
<b>Primary outcome</b>						
Composite of all cause death and MACE						
IR [95% CI]	4.4 [4.3-4.6]	3.5 [3.1-3.8]	4.2 [3.8-4.7]	2.1 [1.4-2.9]	1.5 [1.0-2.0]	7.5 [5.3-10.3]
Model 1, HR [95% CI]	Ref.	<b>0.86 [0.76-0.96]</b>	1.00 [0.87-1.14]	<b>0.53 [0.36-0.78]</b>	<b>0.42 [0.30-0.59]</b>	<b>1.47 [1.06-2.06]</b>
Model 2, HR [95% CI]	Ref.	<b>0.84 [0.74-0.94]</b>	0.93 [0.81-1.07]	<b>0.56 [0.38-0.82]</b>	<b>0.45 [0.32-0.63]</b>	<b>1.65 [1.18-2.32]</b>
<b>Secondary outcomes</b>						
All cause death						
IR [95% CI]	3.5 [3.3-3.6]	2.1 [1.8-2.3]	2.7 [2.3-3.0]	1.1 [0.6-1.7]	0.7 [0.4-1.1]	4.3 [2.7-6.5]
Model 1, HR [95% CI]	Ref.	<b>0.67 [0.58-0.78]</b>	<b>0.83 [0.70-0.98]</b>	<b>0.33 [0.19-0.56]</b>	<b>0.26 [0.16-0.42]</b>	1.04 [0.68-1.61]
Model 2, HR [95% CI]	Ref.	<b>0.66 [0.56-0.76]</b>	<b>0.77 [0.65-0.91]</b>	<b>0.34 [0.20-0.59]</b>	<b>0.28 [0.17-0.45]</b>	1.25 [0.81-1.93]
CV death						
IR [95% CI]	1.2 [1.1-1.3]	0.9 [0.8-1.1]	1.2 [1.0-1.5]	0.3 [0.1-0.7]	0.3 [0.1-0.6]	2.0 [0.9-3.6]
Model 1, HR [95% CI]	Ref.	0.91 [0.72-1.14]	1.13 [0.88-1.46]	<b>0.38 [0.16-0.92]</b>	<b>0.34 [0.16-0.73]</b>	1.36 [0.72-2.56]
Model 2, HR [95% CI]	Ref.	0.88 [0.70-1.11]	1.02 [0.78-1.32]	<b>0.40 [0.17-0.98]</b>	<b>0.39 [0.18-0.83]</b>	1.81 [0.96-3.42]
MACE						
IR [95% CI]	2.2 [2.1-2.4]	2.3 [2.0-2.6]	2.7 [2.4-3.1]	1.4 [0.9-2.2]	1.1 [0.7-1.5]	5.3 [3.5-7.8]
Model 1, HR [95% CI]	Ref.	1.13 [0.97-1.32]	<b>1.27 [1.06-1.51]</b>	0.82 [0.53-1.27]	<b>0.63 [0.43-0.93]</b>	<b>2.06 [1.39-3.04]</b>
Model 2, HR [95% CI]	Ref.	1.11 [0.95-1.29]	1.18 [0.98-1.41]	0.87 [0.56-1.35]	0.68 [0.46-1.00]	<b>2.35 [1.59-3.50]</b>
Thromboembolism						
IR [95% CI]	1.2 [1.1-1.3]	1.6 [1.3-1.8]	1.8 [1.5-2.1]	1.2 [0.7-1.9]	0.8 [0.5-1.2]	3.9 [2.3-6]
Model 1, HR [95% CI]	Ref.	<b>1.33 [1.10-1.61]</b>	<b>1.42 [1.14-1.77]</b>	1.16 [0.72-1.90]	0.76 [0.48-1.21]	<b>2.79 [1.75-4.44]</b>
Model 2, HR [95% CI]	Ref.	<b>1.32 [1.09-1.60]</b>	<b>1.42 [1.14-1.78]</b>	1.18 [0.73-1.93]	0.76 [0.48-1.21]	<b>2.45 [1.53-3.92]</b>
Major bleeding						
IR [95% CI]	1.3 [1.2-1.4]	0.8 [0.6-1.0]	0.7 [0.5-0.9]	1.3 [0.8-2]	0.5 [0.3-0.8]	2.0 [0.9-3.6]
Model 1, HR [95% CI]	Ref.	<b>0.77 [0.61-0.98]</b>	<b>0.68 [0.50-0.93]</b>	1.24 [0.77-1.99]	<b>0.54 [0.31-0.94]</b>	1.39 [0.72-2.70]
Model 2, HR [95% CI]	Ref.	<b>0.77 [0.60-0.98]</b>	<b>0.65 [0.48-0.90]</b>	1.31 [0.81-2.10]	<b>0.56 [0.32-0.98]</b>	1.53 [0.78-2.97]
Intracranial haemorrhage						
IR [95% CI]	0.3 [0.2-0.3]	0.4 [0.3-0.5]	0.4 [0.2-0.5]	0.3 [0.1-0.7]	0.3 [0.1-0.6]	1.0 [0.3-2.3]
Model 1, HR [95% CI]	Ref.	<b>1.54 [1.04-2.26]</b>	1.45 [0.90-2.33]	1.42 [0.57-3.52]	1.36 [0.65-2.84]	<b>3.39 [1.37-8.41]</b>
Model 2, HR [95% CI]	Ref.	<b>1.42 [0.96-2.10]</b>	1.32 [0.81-2.15]	1.34 [0.54-3.32]	1.27 [0.61-2.67]	<b>3.13 [1.25-7.84]</b>
Non ICH major bleeding						
IR [95% CI]	1.0 [1.0-1.1]	0.4 [0.3-0.6]	0.4 [0.2-0.5]	1.0 [0.6-1.6]	0.2 [0.1-0.4]	1.0 [0.3-2.3]
Model 1, HR [95% CI]	Ref.	<b>0.51 [0.37-0.71]</b>	<b>0.43 [0.28-0.66]</b>	1.14 [0.66-1.99]	<b>0.27 [0.11-0.66]</b>	0.79 [0.30-2.13]
Model 2, HR [95% CI]	Ref.	<b>0.53 [0.38-0.73]</b>	<b>0.42 [0.27-0.65]</b>	1.24 [0.71-2.17]	<b>0.29 [0.12-0.71]</b>	0.92 [0.34-2.47]

Bold text depicts statistically significant results at p < 0.05 level. Model 1 adjusted for age, sex, type of AF, history of bleeding, BMI, use of OAC, CHA2DS2-VASc score and Phase of Recruitment (Phase III vs. Phase II). Model 2 adjusted for age, sex, type of AF, history of bleeding, BMI, use of OAC, arterial hypertension, diabetes, history of stroke/TIA, heart failure, PAD, CAD and Phase of Recruitment (Phase III vs. Phase II). CI = confidence intervals; HR = hazard ratio; IR = incidence rate; Ref = reference.

**Table 3: Multivariable Cox regressions on the risk of major outcomes according to Asian ethnicity.**

and Japanese patients had the lowest risk of all-cause and cardiovascular death, with Korean patients also showing a lower risk of major bleeding and non-ICH major bleeding. Patients in the other Asian subgroup had a higher risk of MACE, thromboembolism and major bleeding.

The results on the interaction between phase of recruitment, Asian ethnicity and risk of adverse outcomes are reported in [Supplementary Fig. S7](#). No statistically significant interactions were observed for the outcomes investigated, for both regression models; however, Asian patients recruited in Phase III showed lower risk of both major bleeding (p for

interaction = 0.091) and non-ICH major bleeding (p for interaction = 0.070).

### Discussion

In this analysis, based on a global contemporary, prospective cohort of patients with AF, we showed: 1) patterns of OAC prescription were different between non-Asian and Asian patients, with the latter more frequently undertreated with OAC and NOAC; 2) significant differences in OAC prescription between subgroups of Asian patients, with Japanese more likely to receive OAC and NOAC, and the other subgroups more



often undertreated; 3) the risk of OAC discontinuation during follow-up was higher among Asian patients with AF, with some differences observed among Asian ethnicity subgroups; 4) Asian patients had a heterogeneous risk of adverse outcomes, with our results showing associations with lower risks of the primary composite outcome, death and major bleeding, but with a higher risk of thromboembolic events and ICH; and 5) risks were heterogeneously distributed among ethnically Asian subgroups, suggesting that further differences may be present.

The increasing uptake of NOAC has changed the landscape of antithrombotic risk prevention worldwide. However, geographical differences in pattern of OAC use have already been described, in GLORIA-AF Registry and other studies, and undertreatment of Asian patients has been reported.<sup>13,14,20</sup> Also, Asian patients have been described at higher risk of both thromboembolism and ICH, thus underlining the high risk of adverse outcomes, and the unmet need for better management of these patients.<sup>11,21</sup>

In this analysis, we found that Asian patients were overall less prescribed an OAC compared to non-Asian individuals (which were mainly recruited in Europe and North-America). Moreover, we found significant heterogeneity among Asian subgroups, with Japanese patients receiving an OAC more frequently, and with a 10-fold higher odds of receiving a NOAC over a VKA. We found that Asian patients (including Japanese) were more likely to discontinue OAC during follow-up, suggesting that determinants of OAC underprescription may also influence the risk of discontinuation in Asian patients.

Several reasons can explain these findings, and disentangling the effect of ethnicity to those of the region or country of recruitment is challenging. Different timings in market authorisation of NOACs between countries, and different healthcare policies regarding reimbursement and costs can explain, at least partly, differences observed between Asian and non-Asian patients, and in Asian subgroups.<sup>22</sup> For example, NOACs are self-paid in China,<sup>23</sup> and willingness to pay has been shown to be heterogeneous according to educational level and income of patients, thus potentially influencing both OAC prescription and persistence.<sup>24</sup> Nonetheless, previous evidence has shown that Asian (as well as Black) patients with AF were less likely than White patients to initiate OAC, even in the same geographical setting.<sup>25,26</sup> Also, prescription of lower-dose NOAC is common among Asian patients; the latter may expose them to a higher risk of unfavorable prognosis when dose-reduction criteria are not met.<sup>27,28</sup> Potential reasons for these differences could reside in different perceptions, among treating physicians, of the baseline thromboembolic and haemorrhagic risks of different ethnicities, as well as in imbalances in the access to care.<sup>25</sup> While these findings seem consistent with our

results (and with the potential ethnicity-based differences in OAC prescription), whether our findings can be wholly attributed to the influence of ethnic or geographical factors (or to the contribution of both) remains an open question, and will require further investigation.

Indeed, differences between Asian ethnicities (such as Chinese and other Asian) were reported in the GARFIELD-AF registry, showing how Chinese patients were more likely treated with VKA.<sup>29</sup> Of note, geographical differences in quality of anticoagulation have already been reported, with previous study showing low proportion of VKA-treated Asian patients with good time in therapeutic range.<sup>30</sup> Finally, we observed some imbalances in thromboembolic risk factors between different Asian ethnicities: while Japanese patients exhibited similar age and proportion of patients with high CHA<sub>2</sub>DS<sub>2</sub>-VASc score compared to non-Asians, other ethnicity subgroups were overall younger, and had lower baseline thromboembolic risks. All these factors could also have contributed to OAC prescription and discontinuation in our study.

Taken together, all these factors can explain the different patterns of OAC prescription and discontinuation observed in Asian patients in our study. Of note, OAC utilization has been increasing over last decade in Asian countries, particularly driven by higher adoption of NOACs.<sup>31–33</sup> This is consistent with our results on the interaction between phase of recruitment and odds of OAC and NOAC prescription, considering that Phase III of the GLORIA-AF registry was conducted after the Phase II.

Our findings suggest that, while unsatisfactory OAC treatment is still a global concern, this may represent a concern that disproportionately affects Asian patients. This is important given that our results also show that Asian patients with AF may present a specific risk profile in terms of major outcomes: we found a potential association between Asian ethnicity and higher risk of thromboembolic events and ICH, with also lower risk of all-cause death and overall major bleeding (mostly driven by non-ICH major bleeding).

While these results are in line with previous evidence, which showed a higher risk of stroke/thromboembolism and ICH in Asian patients,<sup>12,34</sup> the association between Asian ethnicity and lower risk of major bleeding, and specifically non-ICH major bleedings raises several hypotheses. First, this may reflect the higher uptake of NOAC in the Asian populations compared to previous studies, as the risk reduction in major bleeding observed with NOACs was higher in Asians compared to non-Asian patients.<sup>1,12,35</sup> Second, the higher risk of thromboembolism, paired with the overall lower risk of major bleeding, may not be due only to ethnic-specific predisposition, but also to the lower OAC use among Asians patients, as in our cohort. Third, despite the overall lower risk of major bleeding, Asians

individuals were still found at higher risk of ICH, similar to previous observations.<sup>34</sup> This is consistent with the hypothesis of specific ethnic-factors which may predispose to ICH, including a potentially higher prevalence of cerebral microbleeds and small cerebral vessel disease, as well as genetic polymorphisms associated to bleeding.<sup>36</sup> Finally, the lower risk of mortality found in Asian patients may be due to differences in baseline characteristics and risk factors between Asian and non-Asian patients. Overall, also considering the exploratory nature of these associations, these results need confirmation in other cohorts and clinical scenarios, and should therefore be interpreted with caution.

Taken together, our results have several clinical implications. Given the unsatisfactory OAC treatment (in terms of prescription and persistence), further efforts should be dedicated to ensure that Asian patients with AF receive adequate thromboembolic risk prevention. This appears particularly important when considering their higher risk of both thromboembolism and ICH. Indeed, patients with AF require careful management to improve their long-term prognosis and the 'Atrial fibrillation Better Care' (ABC) pathway has been proposed to streamline a holistic and integrated care approach to the management of patients with AF, encompassing rational choice regarding OAC, patient-centred strategies to achieve better symptoms control, and optimal management of comorbidities and risk factors.<sup>37</sup> This approach has been already proved effective in reducing the risk of adverse outcomes,<sup>38,39</sup> including thromboembolism and major bleedings.<sup>40</sup> Moreover, its efficacy has been specifically tested and proven in Asian settings,<sup>41</sup> including a cluster randomised trial performed in China.<sup>42</sup> Nonetheless, adherence to the ABC pathway has been found to be unsatisfactory,<sup>40</sup> and given the findings of our study, its large-scale application should be encouraged. Indeed, the latest Asia Pacific Heart Rhythm Society Guidelines for the management of patients with AF recommended the implementation of the ABC pathway in clinical practice, thus reinforcing how these patients require an holistic and integrated approach to improve their outcomes.<sup>43</sup>

Our study also leaves several open questions. Among the others, whether the results observed can be attributed clearly to ethnicity rather than other factors (geographical or country-specific characteristics, socioeconomic status, differences in local practice, healthcare systems, and reimbursement policies). Interestingly, recent US-based analyses have suggested that differences between Asian and non-Asian patients may be mitigated when they are treated in the same geographical setting.<sup>44,45</sup> Further studies are therefore needed to disentangle the effect of ethnicity (e.g., the perceived higher risk of ICH in Asians which may influence OAC prescription) to that of the country and geographical region.<sup>46</sup>

Our study represents a large comparison of Asian and non-Asian individuals, based on a contemporary,

global cohort of newly-diagnosed patients with AF and using self-reported ethnicity. The findings are largely consistent with previous, preliminary observations on the topic, and contribute to expand our knowledge on the potential ethnic differences in AF. Furthermore, we reported on OAC prescription and discontinuation, as well as major outcomes, thus offering us a comprehensive outlook on the management and natural history of patients with AF.

Nonetheless, our study has some limitations. First, this is a post-hoc analysis of an observational prospective study, and therefore we may have limited power to detect differences, especially in some Asian ethnic subgroups (for which our results should be regarded as hypothesis-generating). The analysis is based on self-reported ethnicity, and a small proportion of patients were excluded due to lack of data. Other factors may have influenced patients' choice regarding their self-reported ethnicity, which we were unable to explore. Specifically, we were only able to analyse data according to the region of recruitment and not country, and therefore we could not analyse country-specific differences in terms of healthcare systems and reimbursement policies, and these factors may exert an important role in determining the differences observed, especially between Asian subethnicities. Moreover, we cannot fully exclude the effect of unaccounted confounders in the relationship between Asian ethnicity and outcomes (including OAC prescription and discontinuation); specifically, it is possible that imbalance in clinical characteristics, country-specific factors (most Asian patients were recruited in Asian countries), socio-economical factors, and timing of recruitment may have influenced the results observed, which should therefore be interpreted with caution. However, we provided both interaction analysis according to recruitment phase, and two different covariate-adjusted models, which gave broadly similar results. We considered switching to another antithrombotic regimen as an OAC discontinuation in this analysis, consistently with previous analysis on the same registry,<sup>47</sup> and this may have influenced the associations observed between ethnicity and OAC discontinuation; moreover, the imbalance in OAC discontinuation during follow-up could have influenced in turn the association between ethnicity and outcomes. Further studies are clearly required to address this issue. Finally, our results on secondary outcomes (including thromboembolism and major bleeding events) were not adjusted for multiple comparisons, and therefore should be interpreted with caution.

In this large prospective global registry of patients with AF, Asian patients were less likely prescribed with OAC and NOAC, with some heterogeneity between different ethnic subgroups. Moreover, Asian ethnicity was associated with OAC discontinuation, and lower risk of the composite outcome of all-cause death and MACE. Among exploratory secondary

outcomes, Asian ethnicity was associated with lower risk of major bleeding, but higher risks of thromboembolic events and ICH. Improvements in the management of AF are needed to improve outcomes in Asian patients with AF.

#### Contributors

GFR, BC, and GYHL conceived and designed the analysis, and verified the underlying data; GFR analysed data; GFR and BC interpreted data and drafted the manuscript; MP, DAM, JF, AB, GB, BO, YHC, MVH, TFC, and GYHL revised the manuscript and gave relevant intellectual contribution. GFR, BC, and GYHL had access to the dataset, all authors read and approved the final manuscript, and accept responsibility to submit for publication.

#### Data sharing statement

Data supporting this study by the data contributors Boehringer Ingelheim, and were made and are available through Vivli, Inc. Access was provided after a proposal was approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement.

#### Declaration of interests

GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. AB has been a consultant or speaker for AstraZeneca, Bayer, BMS/Pfizer, Medtronic, Vitorpharma and Alnylam. TFC reported honoraria for lectures from Boehringer Ingelheim, Bayer, Pfizer, and Daiichi Sankyo, outside the submitted work. GB reports small speaker fees from Bayer, Boehringer Ingelheim, Boston, BMS, Daiichi, Sanofi, Janssen outside the submitted work. MVH has been receiving research grants from the Dutch Healthcare Fund, Dutch Heart Foundation, BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim and consulting fees from BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim to the institution. All other authors have nothing to declare. GYHL has been consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are directly received personally. All the disclosures happened outside the submitted work. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871.

#### Acknowledgements

This publication is based on research using data from data contributors Boehringer Ingelheim that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication. This study was funded by Boehringer Ingelheim GmbH. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.eclinm.2023.102039>.

#### References

- Chiang CE, Wang KL, Lip GYH. Stroke prevention in atrial fibrillation: an Asian perspective. *Thromb Haemost*. 2014;111(5):789–797.
- Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J*. 2013;34(35):2746–2751.
- Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. *Eur Heart J*. 2018;39(32):2975–2983.
- Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. *Eur Heart J Qual Care Clin Outcomes*. 2022;8(2):187–194.
- Singh SM, Abdel-Qadir H, Pang A, et al. Population trends in all-cause mortality and cause specific-death with incident atrial fibrillation. *J Am Heart Assoc*. 2020;9(19):e016810.
- Calvert P, Tamirisa K, Al-Ahmad A, Lip GYH, Gupta D. Racial and ethnic disparities in stroke prevention for atrial fibrillation. *Am J Med*. 2022;136(3):225–233.
- Wong KSL, Hu DY, Oommen A, Tan RS, Patel MR, Singer DE, et al. Rivaroxaban for stroke prevention in east Asian patients from the ROCKET AF trial. *Stroke*. 2014;45(6):1739–1747.
- Wong CX, Brown A, Tse HF, et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. *Heart Lung Circ*. 2017;26(9):870–879.
- Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *Am Heart J*. 2014;168(3):303–309.
- Goto S, Merrill P, Wallentin L, et al. Antithrombotic therapy use and clinical outcomes following thromboembolic events in patients with atrial fibrillation: insights from ARISTOTLE. *Eur Heart J Cardiovasc Pharmacother*. 2018;4(2):75–81.
- Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. *Stroke*. 2013;44(7):1891–1896.
- Lip GYH, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. *Int J Cardiol*. 2015;180:246–254.
- Gu HQ, Yang X, Wang CJ, et al. Assessment of trends in guideline-based oral anticoagulant prescription for patients with ischemic stroke and atrial fibrillation in China. *JAMA Netw Open*. 2021;4(7):e2118816.
- Bayer V, Kotalczyk A, Kea B, et al. Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF Phase III registry. *J Am Heart Assoc*. 2022;11(6):e023907.
- Huisman Mv, Lip GYH, Diener HC, et al. Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J*. 2014;167(3):329–334.
- Lip GYH, Kotalczyk A, Teutsch C, et al. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF registry. *Clin Res Cardiol*. 2022;111(5):560–573.
- Huisman Mv, Teutsch C, Lu S, et al. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. *Clin Res Cardiol*. 2022;111(5):548–559.
- Mazurek M, Teutsch C, Diener HC, et al. Safety and effectiveness of dabigatran at 2 years: final outcomes from Phase II of the GLORIA-AF registry program. *Am Heart J*. 2019;218:123–127.
- Ulm K. Simple method to calculate the confidence interval of a standardized mortality ratio (SMR). *Am J Epidemiol*. 1990;131(2):373–375.
- Paquette M, Fadahunsi O, Wang M, et al. Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation. *Thromb Update*. 2021;4:100053.
- Chao TF, Chen SA, Ruff CT, et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. *Eur Heart J*. 2019;40(19):1518–1527.
- Son KB. The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. *BMC Public Health*. 2020;20(1):797.
- Liu T, Yang HL, Gu L, et al. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study. *BMC Cardiovasc Disord*. 2020;20(1):22.
- Zhao J, Wang H, Li X, et al. Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial

- fibrillation in China: a discrete choice experiment. *PLoS Med.* 2021;18(8):e1003730.
- 25 Essien UR, Kim N, Hausmann LRM, et al. Disparities in anticoagulant therapy initiation for incident atrial fibrillation by race/ethnicity among patients in the Veterans Health Administration System. *JAMA Netw Open.* 2021;4(7):e2114234.
  - 26 Tedla YG, Schwartz SM, Silberman P, Greenland P, Passman RS. Racial disparity in the prescription of anticoagulants and risk of stroke and bleeding in atrial fibrillation patients. *J Stroke Cerebrovasc Dis.* 2020;29:104718.
  - 27 Cho MS, Yun JE, Park JJ, et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation. *Stroke.* 2018;50(1):110–118.
  - 28 Cheng WH, Chao TF, Lin YJ, et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. *Stroke.* 2019;50(9):2574–2577.
  - 29 Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Am Heart J.* 2019;213:35–46.
  - 30 Haas S, ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. *Garcia de Frutos P PLoS One.* 2016;11(10):e0164076.
  - 31 Chen M, Li C, Liao P, et al. Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: a medical insurance database study. *Lancet Reg Health West Pac.* 2022;23:100470.
  - 32 Akao M, Ogawa H, Masunaga N, et al. 10-year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients — the Fushimi AF registry. *Circ J.* 2022;86(4):726–736.
  - 33 Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GYH. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study. *PLoS One.* 2017;12(12):e0189495.
  - 34 Shen AYJ, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. *J Am Coll Cardiol.* 2007;50(4):309–315.
  - 35 Wang KL, Lip GYH, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. *Stroke.* 2015;46(9):2555–2561.
  - 36 Bang OY, Hong KS, Heo JH, et al. New oral anticoagulants may be particularly useful for Asian stroke patients. *J Stroke.* 2014;16(2):73–80.
  - 37 Lip GYH. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol.* 2017;14(11):627–628.
  - 38 Romiti GF, Proietti M, Bonini N, et al. Adherence to the atrial fibrillation better care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: a post-hoc analysis from the prospective GLORIA-AF registry. *EClinicalMedicine.* 2023;55:101757.
  - 39 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway. *Am J Med.* 2018;131(11):1359–1366.e6.
  - 40 Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the “Atrial Fibrillation Better Care” pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. *Thromb Haemost.* 2022;122(3):406–414.
  - 41 Yoon M, Yang PS, Jang E, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. *Thromb Haemost.* 2019;119(10):1695–1703.
  - 42 Guo Y, Lane DA, Wang L, et al. Mobile health technology to improve care for patients with atrial fibrillation. *J Am Coll Cardiol.* 2020;75(13):1523–1534.
  - 43 Chao TF, Joung B, Takahashi Y, et al. Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. *Thromb Haemost.* 2021;122(1):20–47.
  - 44 Gu K, Mahtta D, Kaneria A, et al. Racial disparities among Asian Americans with atrial fibrillation: an analysis from the NCDR@PINNACLE registry. *Int J Cardiol.* 2021;329:209–216.
  - 45 Essien UR, Chiswell K, Kaltenbach LA, et al. Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: findings from the get with the guidelines-atrial fibrillation registry. *JAMA Cardiol.* 2022;7(12):1207–1217.
  - 46 Olshansky B, Lip GYH. Disparities in atrial fibrillation management: is race to blame? *Int J Cardiol.* 2021;331:118–119.
  - 47 Paquette M, França LR, Teutsch C, et al. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry. *Am J Cardiol.* 2020;125(3):383–391.